1. Introduction {#s0005}
===============

Insulin resistance (IR) in obesity patients with Type 2 diabetes mellitus (T2DM) associated diseases such as hypertension and hyperlipidemia are well-known as major health problems worldwide ([@b0235]). Aging and IR considered as risk factors for the development of T2DM ([@b0075]). T2DM characterized by hyperglycemia in perspective to IR found to affect at least 285 million worldwide and its frequency is expected to increase continuously ([@b0100]). T2DM is vigorously linked to obesity and pathological lipid deposition in the non-adipose tissues, which is suggested in contributing the development of IR ([@b0030]). In the glucose metabolism, insulin is the main regulatory function in multiple tissues such as adipocyte, liver and muscle through redistributing glucose transporter (*GLUT*4), which regulates the insulin stimulated glucose transport in adipose tissues and skeletal muscles. Glucose transporter protein content is altered under pathological conditions such T2DM ([@b0190], [@b0215]). Once insulin binds to its receptor, it regulates different cellular responses such as glucose uptake, glycogen synthesis and lipogenesis mainly in the targeting tissue. IR in both muscle and adipocyte tissues results in the dysregulation in hormonal control, which leads to the prone of T2DM disease. The pathogenesis mechanisms of IR is poorly discussed ([@b0140]). The facilitative Glucose transport across cellular membrane via the GLUT protein family. GLUT1 protein is accountable uptake in cells. GLUT4 protein forms the cytoplasm vesicles through the sarcolemmal plasma membrane. However, both GLUTs are major glucose transporters ([@b0065]). Mueckler ([@b0145]) in his study has already acknowledged the connection between the IR and *GLUT*4 in the skeletal muscle.

Some natural products as herbs have been used as a source for novel medicine due to their ability to treat enormous types of human diseases. The chemical therapeutic treatments found to have dangerous side-effects, which could not noticed with herbal medicines, therefore it has grabbed the more attention ([@b0130], [@b0135], [@b0225]). Turmeric is known to be the one of the important herbs and its active component is known to be Curcumin, which is used as treatment for the different human diseases. Biological and pharmacological effects of Curcumin have been previously described both *in vivo* and *in vitro* ([@b0175]). The efficiency of Curcumin involves diabetes, cancer and cardiovascular diseases; however, abundant studies have been documented that Curcumin was more effective than Turmeric in treating T2DM ([@b0125], [@b0170], [@b0180]). Numerous biological and pleotropic activities were involved with curcumin as anti-proliferative, anti-inflammatory anti-bacterial and anti-oxidant agents ([@b0200]). Curcumin contents of polyphenol-enriched fraction showed increase in the anti-diabetic effect through increasing GLUT4 levels in C2C12 skeletal muscle myotube cells ([@b0005], [@b0020], [@b0040], [@b0045], [@b0220]). Although, numerous studies have demonstrated the curcumin effect on insulin signaling gene expression (*AMPK, ERK, IRS1, PI3K*) and GLUT4 uptake from the cytoplasm to the cell-membrane ([@b0140], [@b0005], [@b0020], [@b0040], [@b0045], [@b0220], [@b0035]). Limited or no studies were documented with the combination of curcumin and its effect on *GLUT*4 gene expression analysis. Due to the fact that Insulin has the major regulatory role in glucose metabolism in different tissues, it looks crucial to study the effect of curcumin on the expression level of *GLUT1* and *GLUT4* genes.

2. Materials and methods {#s0010}
========================

2.1. Study details {#s0015}
------------------

This study has been carried out with 35 adult-male albino Wistar rats (150--170 g, each). They were obtained from the breeding unit of Ophthalmology National Institute (ONI), Cairo, Egypt. In plastic cages, animals were housed under standard conditions (12 h light-dark cycles, at 22 °C). Normal diet (N-diet) or high-fat diet (HF-diet) were provided to rats for a couple of weeks prior to the experiment. The HF-diet consisted of 37.70% (wt/wt) corn starch, 10% sucrose, 20% protein (casein), high-fats (20% lard and 2% soy-bean oil), 5%cellulose, 1% vitamin mixture, 4% AIN-93 mineral premix, 0.3% L-methionine. The normal chow diet consisted of the same ingredients except using 52.70% corn starch and 7% soy-bean oil instead of lard ([@b0180]). Animals were maintained according to the rules and regulations of the Ain Shams University Ethics Committee for Experimental Animals.

Curcumin (Sigma-Aldrich Chemie Gmbh, Steinheim, Germany) was liquefied in pure water and an oral dose of 80 mg was given per day ([@b0150]).

2.2. Study design {#s0020}
-----------------

Animals were divided into 5 groups with 7 rats each.

Group-I is defined as Normal rats; throughout the experiment, rats were fed-up with N-diet.

Group-II is non-diabetic HF-diet control rats; only citrate-buffer were given to the rats.

Group-III: Non-diabetic Curcumin treated rats; Curcumin was given regularly for 8-weeks by gastric intubation after 48-hours of STZ injection (Sigma Chemical Co., St. Louis, USA).

Group-IV is known as Diabetic control rats; each rat injected with 35 mg/kg BW STZ dissolved in citrate buffer (pH 4.5).

Group-V is defined as diabetic-Curcumin treated rats; Rats were treated as the previous diabetic control group, then Curcumin was given on the regular basis for 8 weeks.

2.3. Sample collection {#s0025}
----------------------

Every weak, body weight of all rats was measured throughout the experiment. After completion of 10 weeks, rats with holding sustenance for 16 h. Serum was separated and stored at −4 °C. Muscle and pancreas were separated and frozen in the liquid nitrogen for further biochemical analysis.

Gene expression analysis was performed with *GLUT*1 and *GLUT*4 genes using muscle and brain tissues.

2.4. Biochemical analysis {#s0030}
-------------------------

At the end of the study, serum glucose concentrations were determined by colorimetric methods, after the enzymatic reaction with peroxidase (Biodiagnostic, Cairo, Egypt), and insulin levels via Immulite insulin kit (on Immulite 1000, Siemens Medical Solutions, Diagnostic Products Corporation, Los Angeles, CA, USA). The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as the product of the fasting serum glucose (mg/dl) and fasting insulin levels (µU/ml) divided by a constant (405). Glycogen concentrations of liver and muscular (from thigh) tissues were determined as described by Plummer ([@b0020]). Serum total protein was estimated using Biuret test (Diamond kit, Cairo, Egypt), triglycerides, total cholesterol, high density lipoprotein cholesterol (HDL-Ch) and low density lipoprotein cholesterol (LDL-Ch) were determined by a colorimetric method (Diamond kits, Cairo, Egypt) ([@b0100]). Liver & pancreas malondialdehyde (MDA) contents were measured by preparation of 10% homogenates in 1.15% KCl, centrifuged at 1000*g* at 4 °C for 20 min, and the resultant supernatants were used for the assay as described by [@b0230].

2.5. Gene-expression studies {#s0035}
----------------------------

RNA extraction was performed using 100 mg of rats' tissue (muscle and brain) were collected in the RNAlater solution. Using the RNA isolation kit, RNA was extracted as per the kit provided by RNeasy mini kit. Nanodrop was used to measure the concentrations and purity of RNA ([@b0105], [@b0110]). cDNA was obtained from a sample of 1 μg of tissue- derived RNA on a conventional thermal cycler. This cDNA will be applied for (RT-PCR). Both the *GLUT*1 and *GLUT*4 specific primers oligonucleotides will be used for the synthesis. PCR amplification will be performed in the triplicates in a total volume of 20 μl with SYBR green master-mix. The *18S rRNA* house keeping gene was used for the normalization.

2.6. Statistical analysis {#s0040}
-------------------------

Analyses were performed with SPSS version 16 software for Windows (SPSS, Chicago, IL). Data were expressed as mean ± S.E. Differences between groups were tested for statistical significance using one-way analysis of variance (ANOVA), followed by Tukey's test. A P \< 0.05 was considered significant for all data analyses.

3. Results {#s0045}
==========

The initial body weight was found to be similar in all groups. Gradual and significant increase in obesity was detected in HF-Diet groups compared to N-Diet groups (p \< 0.001). Significant weight loss was observed in diabetes-control rats compared to obesity rats (p \< 0.001). In obesity rats, significant weight loss was detected using the Curcumin, however, it recovers strongly from the body weight loss in the diabetic rats starting from sixth week until the completion of the experiment ([Table 1](#t0005){ref-type="table"} and [Fig. 1](#f0005){ref-type="fig"}).Table 1Final body weight, serum glucose and insulin concentrations, HOMA-IR, liver & muscle glycogen contents, and serum total protein, in experimental groups of rats.GroupsParametersHF-DietN-diet ControlHF-diet ControlCurcuminDiabetic (STZ)Diabetic(STZ) + CuruminFinal body weight (g)259.57 ± 2.18336.29 **^●●●^** ±1.52278.57**^+++^**±3.05180.86**^+++^** ±4.12216.86**^\*\*\*^**±2.60Glucose (mg/dl)72.70 ± 1.6588.41^●●^ ±2.5073.66**^++^** ±1.78291.55**^+++^** ±4.77160.77**^\*\*\*^**±2.34Insulin (µU/ml)2.49 ± 0.183.66^●●^ ±0.172.45^+++^±0.181.67**^+++^** ±0.141.90 ± 0.22HOMA-IR0.45 ± 0.040.80^●^ ±0.040.44^+^±0.031.21 ^++^±0.110.76**^\*\*\*^**±0.09Liver glycogen (mg/g fresh tissue**)**35.98 ± 1.6029.52^●●^±0.9930.70 ± 0.9317.90**^+++^** ±0.6222.37**\***±0.30muscle glycogen (mg/g fresh tissue**)**6.67 ± 0.326.04 ± 0.295.94 ± 0.281.97**^+++^**±0.213.34**^\*\*\*^**±0.21Total protein (g/dl)8.03 ± 0.177.48 ± 0.227.51 ± 0.213.91**^+++^**±0.095.53**^\*\*\*^**±0.21[^1][^2][^3][^4]Fig. 1Measurement of the body weight on Day1. After couple of weeks and on fourth, sixth, eighth and tenth weeks of the experiment with STZ supervision day.

Hyperglycemic were observed with non-diabetic obese rats (p \< 0.001); results of HOMA-IR confirmed them as IR when compared to the N-diet group ([Table 1](#t0005){ref-type="table"}). The STZ diabetogenic rats clubbed with HF-diet shows IR with clear T2DM through severe hyperglycemia; detects in HOMA-IR ([Table 1](#t0005){ref-type="table"}). Glucose levels were decreased after Curcumin treatment and the status of IR was decreased using HOMA-IR levels in diabetes and obese groups (p \< 0.05--0.001).

In the obese rats, the liver glycogen content was decreased ([Table 1](#t0005){ref-type="table"}). T2DM rats also revealed significant reduction in glycogen and serum total protein content compared to non-diabetic obese controls (p \< 0.001). While diabetic rats Curcumin treatment increased glycogen content in liver compared to non-treated diabetic groups (p \< 0.001).

Hypertriglyceridemia, hypercholesterolemia, and high LDL-Ch levels were observed in obese rats (p \< 0.001). Dyslipidemia was more pronounced in diabetic rats than obese control group with low levels of HDL-C ([Figs. 2](#f0010){ref-type="fig"}A, B and [3](#f0015){ref-type="fig"}A and B). In obese and T2DM groups, the Curcumin treatment has lowered the triglycerides, total cholesterol, and LDL-Ch, while it elevates HDL-C levels compared to diabetic control group. MDA-levels were elevated in liver and pancreas of T2DM group (p \< 0.001), these effects were reversed significantly via administration of Curcumin ([Fig. 4](#f0020){ref-type="fig"}).Fig. 2(A) serum-TG and (B) serum-TC levels were measured in H-diet non-diabetic vs diabetic rats treated with curcumin and controls. N-diet normal group rats were refereed as controls.Fig. 3(A) HDL-c serum and (B) LDL-c levels measured in H-diet non-diabetic; diabetic rats were treated with curcumin treatment. Controls were referred to as N-diet normal group.Fig. 4MDA levels in both liver and pancreas measured in H-diet non-diabetic; diabetic rats were treated with curcumin by controls as N-diet group.

RT-PCR was used to perform comparative gene expression analysis. This experiment showed that the obese and diabetic rats exhibited down-regulation of both glucose transporter genes. Compared to normal control group, down-regulation for *GLUT*1 gene expression of the HF-diet control and the diabetic control was observed with a value of 0.20 and 0.09, respectively. Down-regulation of *GLUT*4 expression was also observed with values of 0.16 and 0.001 for HF-diet control and the diabetic control, respectively compared to normal control group ([Table 2](#t0010){ref-type="table"}).Table 2Average C~T~ & 18S rRNA average C~T~ measured, and ΔC~T~, ΔΔC~T~ & fold difference calculated, for both Glut1&Glut4; in the N-diet, the HF-diet control group and the control diabetic group. The N-diet control group was considered as the reference control.GroupsGlut1Glut4Glut1 average C~T~18S rRNA Average C~T~ΔC~T~ΔΔC~T~2^−ΔΔCt^Glut4 Average C~T~18S rRNA Average C~T~ΔC~T~ΔΔC~T~2^−ΔΔCt^**N-diet**31.2228.163.060136.2835.430.8501**HF-diet**30.3324.975.362.300.2033.6430.133.512.660.16**Diabetic control**30.6524.196.463.400.0933.6523.1210.539.680.001[^5][^6][^7]

However, Curcumin-treated and STZ-induced diabetic groups showed down-regulation of *GLUT*1 gene expression analysis in brain tissue, which reached 0.99 and 0.47 of HF-diet control group, respectively ([Table 3](#t0015){ref-type="table"}). Moreover, down-regulation of the *GLUT4* gene expression reaching 0.02 compared to control group was observed after Curcumin treatment. These results indicated that diabetogenesis down-regulated the gene expression, reaching 0.01 of the corresponding HF-diet control group ([Table 3](#t0015){ref-type="table"}). The Curcumin-treated diabetic group, showed down-regulation of *GLUT1* gene expression of 0.81 that of the diabetic control. However, Curcumin caused up-regulation of *GLUT*4 gene expression. The expression change was 8.07 folds that of the diabetic control ([Table 4](#t0020){ref-type="table"}).Table 3Average C~T~ & 18S rRNA average C~T~ measured, and ΔC~T~, ΔΔC~T~ & fold difference calculated, for both Glut1&Glut4; in the HF-diet control group, nondiabetic control groups treated with curcumin, and the nontreated diabetic group. The HF-diet control group was considerd as the reference control.GroupsGlut1Glut4Glut1 average C~T~18S rRNA average C~T~ΔC~T~ΔΔC~T~2^−ΔΔCt^Glut4 average C~T~18S rRNA average C~T~ΔC~T~ΔΔC~T~2^−ΔΔCt^**Diabetic control**30.6524.196.460133.6523.1210.5301**Curcumin**30.0623.306.760.30.8131.9724.517.46−3.078.40[^8][^9][^10]Table 4Average C~T~ & 18S rRNA average C~T~ measured, and ΔC~T~, ΔΔC~T~ & fold difference calculated, for both Glut1&Glut4; in the diabetic control group, and diabetic groups treated with curcumin. The diabetic control group was considerd as the reference control.GroupsGlut1Glut4Glut1 average C~T~18S rRNA average C~T~ΔC~T~ΔΔC~T~2^−ΔΔCt^Glut4 average C~T~18S rRNA average C~T~ΔC~T~ΔΔC~T~2^−ΔΔCt^**HF-diet**30.3324.975.360133.6430.133.5101**Curcumin**30.8125.445.370.010.9932.3722.959.425.910.02**Diabetic control**30.6530.6524.191.100.4733.6523.1210.537.020.01[^11][^12][^13]

4. Discussion {#s0050}
=============

The current study, Curcumin treatment lowered the insulin level, significant hyperglycemia and acute IR; in H-diet and STZ diabetic rats compared in HF-diet control group + T2DM. However, this study was found to be in accordance with the [@b0080].

In this study, Curcumin treatment strongly improves glucose level and body weight of the diabetic-rats ([@b0120]). The combination of Curcumin and tetrahydro-Curcumin dose of 80 mg/kg BW for 45 days has decreased the glucose levels in STZ/NA-induced rats in T2DM ([@b0150], [@b0155]). Thus, these anti-hyperglycemic effects of Curcuminoids could be the indirect actions, which results in lowering the plasma levels in free fatty-acids in the liver, which lowers the hepatic glucose production ([@b0185]). It has been documented that, Curcumin to improves the insulin release through induction of β-cell in the electrical activity ([@b0055]).

[@b0205] confirmed the role of Curcumin treatment in the glycogen of both liver and muscle in diabetic groups could be linked to the glucokinase activity and glycogen content, which has been repressed through enzyme G6PD and phosphoenolpyruvate carboxykinase. Curcumin is known to increase the liver glycogen synthesis in fasting BALB/c through inhibition of glycogen synthase kinase-3-β ([@b0060]). The current study recommends the advancement of Curcumin treatment in IR increases the serum and protein levels and confirms positive investigation ([@b0150]).

The hypolipidemic effect on both Curcumin and tetrahypocurcumin on STZ6/NA diabetic rats has been documented. Their treatments resulted in lowering the serum and liver cholesterol, TG, phospholipids, free fatty-acids, TC, VLDL and LDL-C levels. HDL-c levels were lowers in diabetic rats, which leads to the normalization after the treatment. Our study founds be similar to previous studies ([@b0185], [@b0205]). However, other study confirms Curcumin stimulates the hepatic cholesterol-7α-hydroxylase activity, which reflects the high levels of hepatic LDL-R and lipoprotein lipase; thus, leads to the hypocholesterolemic and hypotriglyceridemic effects in the animals with diabetes ([@b0045]).

This study also documents the reduction of lipid-peroxidation levels, which might be due to the presence of β-diketone and phenolic hydroxyl groups. Curcumin has antioxidant and anti-inflammatory properties more effective than vitamin-E ([@b0010]) via increasing the intra-cellular glutathione, normalizing antioxidant enzymes and scavenging of free-radicals by preventing the lipid peroxidation ([@b0160]). Moreover, low levels of oxidative stress by diabetic rats, which may be attributed to lower the influx of glucose into the polyol pathway. This leads to high levels of NADPH-NAPD ratio and an elevated activity in the antioxidant enzyme glutathione peroxidase ([@b0015]). This protective effect of Curcumin against oxidative-stress is in agreement with previous study using type1 diabitic rats ([@b0025]).

Down-regulation of *GLUT1* gene was observed in the brain tissue in HF-diet and the diabetic control groups compared to the N-diet control group, could be due to IR and obesity, which arises in HF-diet treatment and STZ-management. The current study results were similarly documented in the previous study with the IR.

[@b0165] concludes that *GLUT1* gene expression was reduced by 77% in the STZ-induced diabetes rats in a weak when compared in the non-diabetic rats. The similar experiment performed for 8 weeks shows the 60% of *GLUT1* expression levels when compared with non-diabetic rats ([@b0050]). *GLUT1* gene expression studies were majorly reported its down-regulation in the brains of diabetic rats ([@b0090], [@b0095]).

In the diabetic rats, chronic hyperglycemia was documented with down-regulation in both *GLUT*1 and *GLUT*3 mRNA and protein expression levels in the brain, which is known to have the negative effect in the glucose levels. The down-regulation is known to maintain the abnormal levels of hyperglycemia for long-term to evade cell-damage occurs with the excess glucose enters into the cells is known as self-protective mechanism in the body, which lowers the glucose transport ([@b0095]).

The *GLUT*4 gene expression analysis showed down-regulation in the femoral muscles in both the diabetic and obese non-diabetic control group compared to normal-diet group, these results are similar to previous studies ([@b0085], [@b0210], [@b0240]).

*GLUT4* mRNA was decreased in the triceps in the skeletal muscle in the HF-diet rats in L6 myotubes. These results indicate HF-diet may lower the *GLUT4* gene transcription and/or degrade the *GLUT*4 mRNA ([@b0085]).

The expression of *GLUT*4 was evidently moderated in Zucker Diabetic fatty rats compared to control ([@b0210]) and low levels of GLUT4 protein expression was found in muscle, liver and adipose tissue in T2DM rat model ([@b0240]).

In the present study, down-regulation of *GLUT1* and *GLUT4* genes have been recognized with Curcumin treatment, which is accredited to high fat-levels in obesity. The *GLUT1* expression studies in non-treated diabetic group was down-regulated to 0.47 in HF-diet of control group and *GLUT4* expression analysis in the non-diabetic group was down regulated to 0.01 in control obese group of HF-diet.

The current study reported that Curcumin treatment downregulated *GLUT1* expression in diabetic rats, this is the first to documentation for this result. The GLUT4 protein levels obtained through western-blotting found to be increased after Curcumin treatment, suggesting the activation of MI-mAChR for increasing levels of glucose uptake by phospholipase C--phosphoinositide 3-kinase (PLC-PI3K) pathway in the skeletal muscle ([@b0070]). [@b0070] documented another possible mechanism of Curcumin stimulation of *GLUT4* expression depending on Kramer et al. study ([@b0115]), they indicated probable mechanism for anti-hyperglycemic effect of rosiglitazone, which was mediated by peroxisome proliferator-activated receptor gamma (PPAR-γ) activation. PPAR-γ has been reported to increase the expression and translocation of the glucose transporters *GLUT*1 and *GLUT*4 to liver and skeletal muscle cells and lower in the plasma glucose levels. [@b0195] study documented the Curcumin enhances the expression of PPAR-γ in human biliary cancer cells. This could tempt one to suggest that, Curcumin has a potential role in activating down-stream insulin signaling pathway as its anti-hyperglycemic property.

5. Conclusion {#s0055}
=============

Curcumin ameliorated IR, the metabolic derangements recorded in obesity and diabetes, and decreased lipid peroxidation in the diabetic status. Curcumin up-regulated Glut4 expression compared to the diabetic group. Future studies of more glucose transporter genes are advocated to clarify the mechanism(s) of the pathogenesis of type 2 diabetes.
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[^1]: Data are presented as mean ± S.E. (n = 7).

[^2]: Significantly different from N-diet control: ^●^p \< 0.05; ^●●^p \< 0.01; ^●●●^p \< 0.001.

[^3]: Significantly different from HF-diet control: ^+^p \< 0.05; ^++^p \< 0.01; ^+++^p \< 0.001.

[^4]: Significantly different from non-treated diabetic control:**\*** p \< 0.05;**^\*\*\*^** p \< 0.001.

[^5]: Where ΔC~T~ = Glut1 or Glut4 C~T~- 18S rRNA C~T~
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[^13]: 2^−ΔΔCt^ = Fold difference in Glut 1 or Glut 4 relative to the nontreated control.
